Secondary outcomes

[키워드] 24 hours 48 hour 48 hours absence admitted to ICU aetiology age ALT Analysis Anosmia anticipated antiviral therapy Antiviral treatment antivirals Appendix Arm arrhythmia AST Asthma Asymptomatic Autoimmune blinded to treatment Blinding blood sample BMI Breastfeeding childbearing potential Cholangitis chronic chronic hepatitis Chronic kidney disease chronic liver disease chronic respiratory disease cirrhosis clinical condition collected combination therapy Comorbidity concealed Concomitant concomitant medications conducted COPD coryza cough COVID-19 COVID-19 disease COVID-19 vaccine criteria current Date Day decrease defined Deleterious detectable diabetes died disease dissemination dose double-blind Duration early treatment effective EGFR element enrolled enrolment Ethnicity examined exclusion criteria factorial design Favipiravir female female participant Fever followed by Free Gender headache heart disease Hepatitis hepatotoxicity HIV infection hospital hospitalisation hypersensitivity hypertension in viral include inclusion criteria ingredient investigator investigators Ischaemic heart disease Kidney disease liver Liver disease London Lopinavir Lopinavir/ritonavir malaise male participant male participants measure medication Mutation myalgia Myocardial infarction no symptom non-hospitalised not limited number obesity objective observational studies observational study oral outcome Outpatient outpatients participant Participants partner percentage pharmacokinetic phase IIa Placebo placebo-controlled placebo-controlled trial positive presence or absence Primary outcome Proportion of participant Protease inhibitor protocol randomised randomised controlled trial Rate Registered Registration respiratory Respiratory disease risk Ritonavir Safety Saliva saliva samples Sample size SARS-CoV-2 secondary Secondary outcomes Shortness of breath smoker smoking smoking status Stage status steatohepatitis Stool Study protocol supplementary material Symptom symptom onset symptomatic tested therapy Toxicity Treatment treatment allocation Trial trial medication Trial registration undetectable United Kingdom upper respiratory tract vaccine trial valvular valvular heart disease Viral Viral load website with COVID-19
[DOI] 10.1186/s13063-021-05139-2 PMC 바로가기 [Article Type] Letter